Danaher Completes Major Acquisition of Genedata to Accelerate Biopharma Innovation

Aug 21, 2024 11:58 CST Updated 11:58

GeneData

Blockchain Big Data Gene Analysis Platform

Source: CACLP Information

On August 19, Genedata AG, a leading provider of biopharmaceutical R&D software solutions, announced that it had been acquired by Danaher.Genedata’s products are expected to be a valuable addition to Danaher’s extensive workflow solutions, helping to accelerate the drug discovery, development, and production of critical new therapies. Over the past few years, Genedata and Danaher have successfully collaborated on multiple occasions.

Genedata, established in 1997 and headquartered in Basel, Switzerland, is a pioneer in transforming data into intelligence for the life sciences industry. Genedata combines computational, scientific, and technical expertise with extensive knowledge across biopharmaceutical R&D to deliver enterprise software and scalable, open, user-friendly solutions that align with industry workflows, supporting large-scale experimental processes in life science research to enhance R&D efficiency. Genedata serves top global biopharmaceutical companies and innovative biotechnology organizations, with clients including Pfizer, Roche, Merck, GSK, and Eli Lilly.Sanofi, Bayer, Lonza and other large pharmaceutical companies; Agenua, Ligand Pharmaceuticals, Moderna and other biotechnology companies.

Greg Milosevich, Vice President and Group Executive of DH Life Sciences LLC, a subsidiary of Danaher, stated that they have consistentlyVeryAppreciate Genedata's innovative software systems based on deep scientific expertise, and join Genedata in its commitment to supporting biopharmaceutical companies by providing innovative solutions to accelerate therapy development and help researchers gain high-quality insights.Thereby accelerating the development of urgently needed therapies.

The acquisition of Genedata by Danaher, although the specific amount has not been disclosed, marks Danaher's further expansion in the specialized diagnostics field, while also providing Genedata with a broader platform to continue its leading position in the life sciences informatics domain.

Disclaimer: The articles published on this WeChat platform that are cited from other sources are reprinted for sharing purposes only, and do not represent the position of the platform. If there are any copyright issues or other problems, please contact us as soon as possible, and we will make corrections immediately. Thank you.